Cargando…

Identification of a RAC/AKT-like gene in Leishmania parasites as a putative therapeutic target in leishmaniasis

BACKGROUND: Leishmaniasis is one of the world’s most neglected diseases caused by at least 20 different species of the protozoan parasite Leishmania. Although new drugs have become recently available, current therapy for leishmaniasis is still unsatisfactory. A subgroup of serine/threonine protein k...

Descripción completa

Detalles Bibliográficos
Autores principales: Varela-M, Rubén E., Ochoa, Rodrigo, Muskus, Carlos E., Muro, Antonio, Mollinedo, Faustino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633885/
https://www.ncbi.nlm.nih.gov/pubmed/29017516
http://dx.doi.org/10.1186/s13071-017-2379-y
_version_ 1783269973971435520
author Varela-M, Rubén E.
Ochoa, Rodrigo
Muskus, Carlos E.
Muro, Antonio
Mollinedo, Faustino
author_facet Varela-M, Rubén E.
Ochoa, Rodrigo
Muskus, Carlos E.
Muro, Antonio
Mollinedo, Faustino
author_sort Varela-M, Rubén E.
collection PubMed
description BACKGROUND: Leishmaniasis is one of the world’s most neglected diseases caused by at least 20 different species of the protozoan parasite Leishmania. Although new drugs have become recently available, current therapy for leishmaniasis is still unsatisfactory. A subgroup of serine/threonine protein kinases named as related to A and C protein kinases (RAC), or protein kinase B (PKB)/AKT, has been identified in several organisms including Trypanosoma cruzi parasites. PKB/AKT plays a critical role in mammalian cell signaling promoting cell survival and is a major drug target in cancer therapy. However, the role of protozoan parasitic PKB/AKT remains to be elucidated. RESULTS: We have found that anti-human AKT antibodies recognized a protein of about 57 kDa in Leishmania spp. parasites. Anti-human phospho-AKT(Thr308) antibodies identified a protein in extracts from Leishmania spp. that was upregulated following parasite exposure to stressful conditions, such as nutrient deprivation or heat shock. Incubation of AKT inhibitor X with Leishmania spp. promastigotes under stressful conditions or with Leishmania-infected macrophages led to parasite cell death. We have identified and cloned a novel gene from Leishmania donovani named Ld-RAC/AKT-like gene, encoding a 510-amino acid protein of approximately 57.6 kDa that shows a 26.5% identity with mammalian AKT1. Ld-RAC/AKT-like protein contains major mammalian PKB/AKT hallmarks, including the typical pleckstrin, protein kinase and AGC kinase domains. Unlike mammalian AKT that contains key phosphorylation sites at Thr308 and Ser473 in the activation loop and hydrophobic motif, respectively, Ld-RAC/AKT-like protein has a Thr residue in both motifs. By domain sequence comparison, we classified AKT proteins from different origins in four major subcategories that included different parasites. CONCLUSIONS: Our data suggest that Ld-RAC/AKT-like protein represents a Leishmania orthologue of mammalian AKT involved in parasite stress response and survival, and therefore could become a novel therapeutic and druggable target in leishmaniasis therapy. In addition, following comparative sequence analyses, we found the RAC/AKT-like proteins from Leishmania constitute a subgroup by themselves within a general AKT-like protein family. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13071-017-2379-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5633885
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56338852017-10-19 Identification of a RAC/AKT-like gene in Leishmania parasites as a putative therapeutic target in leishmaniasis Varela-M, Rubén E. Ochoa, Rodrigo Muskus, Carlos E. Muro, Antonio Mollinedo, Faustino Parasit Vectors Research BACKGROUND: Leishmaniasis is one of the world’s most neglected diseases caused by at least 20 different species of the protozoan parasite Leishmania. Although new drugs have become recently available, current therapy for leishmaniasis is still unsatisfactory. A subgroup of serine/threonine protein kinases named as related to A and C protein kinases (RAC), or protein kinase B (PKB)/AKT, has been identified in several organisms including Trypanosoma cruzi parasites. PKB/AKT plays a critical role in mammalian cell signaling promoting cell survival and is a major drug target in cancer therapy. However, the role of protozoan parasitic PKB/AKT remains to be elucidated. RESULTS: We have found that anti-human AKT antibodies recognized a protein of about 57 kDa in Leishmania spp. parasites. Anti-human phospho-AKT(Thr308) antibodies identified a protein in extracts from Leishmania spp. that was upregulated following parasite exposure to stressful conditions, such as nutrient deprivation or heat shock. Incubation of AKT inhibitor X with Leishmania spp. promastigotes under stressful conditions or with Leishmania-infected macrophages led to parasite cell death. We have identified and cloned a novel gene from Leishmania donovani named Ld-RAC/AKT-like gene, encoding a 510-amino acid protein of approximately 57.6 kDa that shows a 26.5% identity with mammalian AKT1. Ld-RAC/AKT-like protein contains major mammalian PKB/AKT hallmarks, including the typical pleckstrin, protein kinase and AGC kinase domains. Unlike mammalian AKT that contains key phosphorylation sites at Thr308 and Ser473 in the activation loop and hydrophobic motif, respectively, Ld-RAC/AKT-like protein has a Thr residue in both motifs. By domain sequence comparison, we classified AKT proteins from different origins in four major subcategories that included different parasites. CONCLUSIONS: Our data suggest that Ld-RAC/AKT-like protein represents a Leishmania orthologue of mammalian AKT involved in parasite stress response and survival, and therefore could become a novel therapeutic and druggable target in leishmaniasis therapy. In addition, following comparative sequence analyses, we found the RAC/AKT-like proteins from Leishmania constitute a subgroup by themselves within a general AKT-like protein family. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13071-017-2379-y) contains supplementary material, which is available to authorized users. BioMed Central 2017-10-10 /pmc/articles/PMC5633885/ /pubmed/29017516 http://dx.doi.org/10.1186/s13071-017-2379-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Varela-M, Rubén E.
Ochoa, Rodrigo
Muskus, Carlos E.
Muro, Antonio
Mollinedo, Faustino
Identification of a RAC/AKT-like gene in Leishmania parasites as a putative therapeutic target in leishmaniasis
title Identification of a RAC/AKT-like gene in Leishmania parasites as a putative therapeutic target in leishmaniasis
title_full Identification of a RAC/AKT-like gene in Leishmania parasites as a putative therapeutic target in leishmaniasis
title_fullStr Identification of a RAC/AKT-like gene in Leishmania parasites as a putative therapeutic target in leishmaniasis
title_full_unstemmed Identification of a RAC/AKT-like gene in Leishmania parasites as a putative therapeutic target in leishmaniasis
title_short Identification of a RAC/AKT-like gene in Leishmania parasites as a putative therapeutic target in leishmaniasis
title_sort identification of a rac/akt-like gene in leishmania parasites as a putative therapeutic target in leishmaniasis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633885/
https://www.ncbi.nlm.nih.gov/pubmed/29017516
http://dx.doi.org/10.1186/s13071-017-2379-y
work_keys_str_mv AT varelamrubene identificationofaracaktlikegeneinleishmaniaparasitesasaputativetherapeutictargetinleishmaniasis
AT ochoarodrigo identificationofaracaktlikegeneinleishmaniaparasitesasaputativetherapeutictargetinleishmaniasis
AT muskuscarlose identificationofaracaktlikegeneinleishmaniaparasitesasaputativetherapeutictargetinleishmaniasis
AT muroantonio identificationofaracaktlikegeneinleishmaniaparasitesasaputativetherapeutictargetinleishmaniasis
AT mollinedofaustino identificationofaracaktlikegeneinleishmaniaparasitesasaputativetherapeutictargetinleishmaniasis